Miraculins, Sigma-Aldrich, UCSF, Thomson Reuters, Harvard, Diagnostics-For-All, George Mason University, ImmunoCellular Therapeutics, GeneGo, Dana-Farber, Luminex, LifeSpan | GenomeWeb
Miraculins Changes Biz Model, Shifting Away from Proteomics Discovery
Canadian biomarker research and diagnostics firm Miraculins said this week it is dropping its proteomics research and discovery business to concentrate on assay development and commercialization.
The company will in-license, acquire, and develop cancer and non-cancer “diagnostic opportunities that have completed early-stage research and address unmet clinical needs,” the company said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.